BTTC Clinical Trials
An open trial follows a predefined protocol so that the research team and the patient have a complete understanding of the details of the program. Our studies are focused on investigating the effectiveness and safety of treatment regimens as well as quality of life involving malignant gliomas, the most common and most aggressive type of adult brain tumors. The three-year survival rate of glioblastoma multiforme patients is less than two percent and our hope is to improve those numbers.
BTTC Clinical Trials
The study’s primary objective is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied. A phase II trial of pazopanib and topatecan in adult patients with recurrent glioblastoma.
This study’s primary objective is to determine if prophylactic administration of lacosamide reduces the risk of seizures in patients with a high-grade glioma. Newly diagnosed, post-operative patients are tested during the first year after tumor diagnosis.
This study will evaluate the occurrence of symptoms and their relations to disease progression, as well as the tolerance to treatment regimen. A phase I-II trial everolimus and sorafenib in patients with recurrent high-grade gliomas.
This study will look at evaluating the occurrence of symptoms and their relations to disease progression, as well as the tolerance to the treatment regimen. Phase I/II adaptive randomized trial of bevacizumab versus bevacizumab plus vorinostat in adults with recurrent glioblastoma.
Completed BTTC Clinical Trials
The study evaluated the effects and determined overall survival rates of newly diagnosed malignant glioma patients when administering a combination of bevacizumab (Avastin) and erlotinib (Tarceva) following the completion of radiation therapy with temozolomide (Temodar).
The study determined if temozolomide (Temodar) administered alone or in combination with thalidomide (Thalomid™), isotretinion (Accutane) and/or celecoxib (Celebrex) was effective in the continued treatment of newly diagnosed glioblastoma multiforme patients who already had incurred radiation therapy. Also, the toxicity of this adjuvant treatment was studied.